Emerging role of capecitabine in gastric cancer

Pasquale Comella, Luca Franco, Rossana Casaretti, Simona De Portu, Enrica Menditto

Research output: Contribution to journalArticle

Abstract

For many years, a regimen of fluorouracil and cisplatin has been the standard of care for the treatment of patients with metastatic gastric cancer. More recently, triplet regimens that incorporate fluorouracil and cisplatin with epirubicin (ECF) or docetaxel are being used in the management of patients with metastatic disease; ECF is also being used as preoperative treatment of resectable disease. Capecitabine, a prodrug of fluorouracil that can be taken orally, has been assessed as an alternative to intravenous fluorouracil and has demonstrated noninferiority to its parent compound. Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. Oral capecitabine appears to be more convenient to administer than infused fluorouracil because it may obviate the need for central venous access and its associated risk of complications. All of these findings support consideration of capecitabine among the available drug treatment options for patients with metastatic and those with operable gastric cancers.

Original languageEnglish
Pages (from-to)318-330
Number of pages13
JournalPharmacotherapy
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Fluorouracil
Stomach Neoplasms
docetaxel
Cisplatin
Epirubicin
Prodrugs
Standard of Care
Pharmaceutical Preparations
Therapeutics
Capecitabine
Safety

Keywords

  • Capecitabine
  • Gastric cancer
  • Therapeutic management

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Comella, P., Franco, L., Casaretti, R., De Portu, S., & Menditto, E. (2009). Emerging role of capecitabine in gastric cancer. Pharmacotherapy, 29(3), 318-330. https://doi.org/10.1592/phco.29.3.318

Emerging role of capecitabine in gastric cancer. / Comella, Pasquale; Franco, Luca; Casaretti, Rossana; De Portu, Simona; Menditto, Enrica.

In: Pharmacotherapy, Vol. 29, No. 3, 03.2009, p. 318-330.

Research output: Contribution to journalArticle

Comella, P, Franco, L, Casaretti, R, De Portu, S & Menditto, E 2009, 'Emerging role of capecitabine in gastric cancer', Pharmacotherapy, vol. 29, no. 3, pp. 318-330. https://doi.org/10.1592/phco.29.3.318
Comella, Pasquale ; Franco, Luca ; Casaretti, Rossana ; De Portu, Simona ; Menditto, Enrica. / Emerging role of capecitabine in gastric cancer. In: Pharmacotherapy. 2009 ; Vol. 29, No. 3. pp. 318-330.
@article{7c3f183a69b24445b14a737068451339,
title = "Emerging role of capecitabine in gastric cancer",
abstract = "For many years, a regimen of fluorouracil and cisplatin has been the standard of care for the treatment of patients with metastatic gastric cancer. More recently, triplet regimens that incorporate fluorouracil and cisplatin with epirubicin (ECF) or docetaxel are being used in the management of patients with metastatic disease; ECF is also being used as preoperative treatment of resectable disease. Capecitabine, a prodrug of fluorouracil that can be taken orally, has been assessed as an alternative to intravenous fluorouracil and has demonstrated noninferiority to its parent compound. Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. Oral capecitabine appears to be more convenient to administer than infused fluorouracil because it may obviate the need for central venous access and its associated risk of complications. All of these findings support consideration of capecitabine among the available drug treatment options for patients with metastatic and those with operable gastric cancers.",
keywords = "Capecitabine, Gastric cancer, Therapeutic management",
author = "Pasquale Comella and Luca Franco and Rossana Casaretti and {De Portu}, Simona and Enrica Menditto",
year = "2009",
month = "3",
doi = "10.1592/phco.29.3.318",
language = "English",
volume = "29",
pages = "318--330",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Emerging role of capecitabine in gastric cancer

AU - Comella, Pasquale

AU - Franco, Luca

AU - Casaretti, Rossana

AU - De Portu, Simona

AU - Menditto, Enrica

PY - 2009/3

Y1 - 2009/3

N2 - For many years, a regimen of fluorouracil and cisplatin has been the standard of care for the treatment of patients with metastatic gastric cancer. More recently, triplet regimens that incorporate fluorouracil and cisplatin with epirubicin (ECF) or docetaxel are being used in the management of patients with metastatic disease; ECF is also being used as preoperative treatment of resectable disease. Capecitabine, a prodrug of fluorouracil that can be taken orally, has been assessed as an alternative to intravenous fluorouracil and has demonstrated noninferiority to its parent compound. Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. Oral capecitabine appears to be more convenient to administer than infused fluorouracil because it may obviate the need for central venous access and its associated risk of complications. All of these findings support consideration of capecitabine among the available drug treatment options for patients with metastatic and those with operable gastric cancers.

AB - For many years, a regimen of fluorouracil and cisplatin has been the standard of care for the treatment of patients with metastatic gastric cancer. More recently, triplet regimens that incorporate fluorouracil and cisplatin with epirubicin (ECF) or docetaxel are being used in the management of patients with metastatic disease; ECF is also being used as preoperative treatment of resectable disease. Capecitabine, a prodrug of fluorouracil that can be taken orally, has been assessed as an alternative to intravenous fluorouracil and has demonstrated noninferiority to its parent compound. Several trials have demonstrated the safety and efficacy of regimens combining capecitabine with other known active drugs against gastric cancer in doublet and triplet combinations. Oral capecitabine appears to be more convenient to administer than infused fluorouracil because it may obviate the need for central venous access and its associated risk of complications. All of these findings support consideration of capecitabine among the available drug treatment options for patients with metastatic and those with operable gastric cancers.

KW - Capecitabine

KW - Gastric cancer

KW - Therapeutic management

UR - http://www.scopus.com/inward/record.url?scp=62549105260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549105260&partnerID=8YFLogxK

U2 - 10.1592/phco.29.3.318

DO - 10.1592/phco.29.3.318

M3 - Article

C2 - 19249950

AN - SCOPUS:62549105260

VL - 29

SP - 318

EP - 330

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 3

ER -